Key Highlights

• DCOY shares rose 6.40% intraday to $7.65.

• The company raised $3.5 million in a private placement priced at $5.91 per share, with milestone-based warrants attached.

• Decoy Therapeutics separately lined up $21 million in milestone-based PIPE funding.

• The company carries a market capitalization of approximately $4.07 million.

New Financing Rounds Support Pipeline

Decoy Therapeutics Inc. (NASDAQ:DCOY) shares rose Wednesday after the company disclosed a series of financing transactions, including a $3.5 million private placement priced at $5.91 per share with attached milestone-based warrants, along with a separate $21 million milestone-based PIPE funding arrangement.

Decoy Therapeutics is a Cambridge, Massachusetts-based preclinical-stage biotechnology company developing a new category of antivirals known as Designable Multi-Antivirals, engineered to target shared viral mechanisms across multiple pathogens using its proprietary peptide conjugate design platform.

Small-Cap Structure Reflects Early-Stage Profile

The company, formerly known as Salarius Pharmaceuticals before its January 2026 rebranding following a strategic merger, is advancing an initial pipeline focused on respiratory viruses, including COVID-19, influenza and RSV, alongside additional oncology-focused programs. Decoy Therapeutics currently trades at a market capitalization of approximately $4.07 million, reflecting its early clinical stage and limited share count following recent capital raises.

Conclusion

The combination of near-term private placement proceeds and milestone-based PIPE funding provides Decoy Therapeutics with additional capital to advance its antiviral pipeline, though the company's micro-cap valuation and preclinical stage reflect the significant execution risk still ahead. Investors will be watching for progress converting the newly secured funding into clinical development milestones.

 

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.